USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
09 Nov 2022 | 03:45 PM GMT

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 1)

Anchored by:

Malin Johansson
Vice President
NOVO NORDISK

Participants:

Malin Johansson Vice PresidentNovo Nordisk
Malin Johansson
Vice PresidentNovo Nordisk
Jo Peddhinti AdvisoryHLTH Community
Jo Peddhinti
AdvisoryHLTH Community
Jock Thompson CEOHyduro, Inc.
Jock Thompson
CEOHyduro, Inc.
John Gordon Commercial Lead, International MarketsPfizer
John Gordon
Commercial Lead, International MarketsPfizer
Karl Hess Senior AdvisorOutcome Capital
Karl Hess
Senior AdvisorOutcome Capital
Kevin Horgan Stealth Startup,University of PennsylvaniaLOVE
Kevin Horgan
Stealth Startup,University of PennsylvaniaLOVE
Mark Slaughter Chief Strategy and Growth OfficerMika
Mark Slaughter
Chief Strategy and Growth OfficerMika
Martin Svorc Director | Global Business Dev. FertilityMerck KGaA
Martin Svorc
Director | Global Business Dev. FertilityMerck KGaA
Rafal Zasadny Sr. RA managerBayer Consumer Care AG
Rafal Zasadny
Sr. RA managerBayer Consumer Care AG
Sarah Kikkers Digital Health ConsultantHealthXL
Sarah Kikkers
Digital Health ConsultantHealthXL
Valentine Emmanuel Experience Design & Strategy LeadDaiichi Sankyo
Valentine Emmanuel
Experience Design & Strategy LeadDaiichi Sankyo
Vasyl Pyrozhyk Vice PresidentSMBC
Vasyl Pyrozhyk
Vice PresidentSMBC
Vasyl Pyrozhyk Vice President - HealthcareSumitomo Mitsui Banking Corporation
Vasyl Pyrozhyk
Vice President - HealthcareSumitomo Mitsui Banking Corporation

About this Meeting

Outcome focused, 2 part meetings - walk away with insights. 

Participate in a Digital Health Sprint in order to: 
  •  Deep dive into a topic over 2 focused sessions. 
  • Engage with a small group of 10 global thought-leaders throughout. 
  • This sprint is outcome-focused: HealthXL and participants create exclusive outputs.  Grow your network with our break out sessions. 
Unarguably, DTx solutions have clear benefits for patients. In the last few years, pharma companies have realised the potential of DTx to improve their offerings, especially companion DTx.  But the approach taken by pharma towards standalone DTx is a bit more cautious. What role does pharma have in standalone DTx? What are the needs and recommendations for pharma to launch successful standalone DTx? In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group.  

Some of the major challenges we may tackle (these are some examples - the group will agree on the problems they want to address):  

  • Immaturity of reimbursement models and figuring out a sustainable ROI model 
  • Showing pharma the value of standalone DTx beyond new revenues 
  • Traditional sales models that are inadequate for standalone DTx   
  • Finding the right talent and building specialised teams 
  • Rigidity of internal traditional processes (e.g. regulatory, compliance, medical, legal, etc).

Please note: Part 2 of this session will take place on November 30th

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.